Ivane Gamkrelidze
A5031867546- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Hepatitis Viruses Studies and Epidemiology
- Vaccine Coverage and Hesitancy
- Mental Health Treatment and Access
- HIV/AIDS Impact and Responses
- Substance Abuse Treatment and Outcomes
- COVID-19 epidemiological studies
- Health Systems, Economic Evaluations, Quality of Life
- Influenza Virus Research Studies
- SARS-CoV-2 and COVID-19 Research
- Tuberculosis Research and Epidemiology
- Gastroesophageal reflux and treatments
- HIV/AIDS drug development and treatment
- Pharmaceutical Economics and Policy
- Pneumonia and Respiratory Infections
- HIV/AIDS Research and Interventions
- Global Public Health Policies and Epidemiology
- Science, Research, and Medicine
- Cardiovascular Function and Risk Factors
- HIV, Drug Use, Sexual Risk
- Healthcare Systems and Reforms
- Suicide and Self-Harm Studies
- Genetics, Aging, and Longevity in Model Organisms
Center for Disease Analysis
2017-2025
•With only 10 years left to meet the WHO's hepatitis elimination targets, COVID-19 is impacting progress.•A 1-year delay in HCV programs could cause excess morbidity and mortality.•A 72,000 deaths from HCV.•Most would be lower middle income high-income groups. Background & AimsCoronavirus disease 2019 (COVID-19) has placed a significant strain on national healthcare systems at critical moment context of elimination. Mathematical models can used evaluate possible impact programmatic delays...
ABSTRACT BACKGROUND & AIMS Elimination of HCV by 2030, as defined the World Health Organization (WHO), is attainable with availability highly efficacious therapies. This study reports progress made in timing elimination 45 high‐income countries between 2017 and 2019. METHODS Disease progression models infection for each country were updated latest data on chronic prevalence, annual diagnosis treatment levels, assumed to remain constant future. Modelled outcomes analysed determine year...
Vaccination is one of the most effective public health interventions. We investigate impact vaccination activities for
Hepatitis D virus (HDV) infection occurs as a coinfection with hepatitis B and increases the risk of hepatocellular carcinoma, decompensated cirrhosis, mortality compared to (HBV) monoinfection. Reliable estimates prevalence HDV disease burden are essential formulate strategies find coinfected individuals more effectively efficiently. The global HBV infections was estimated be 262,240,000 in 2021. Only 1,994,000 were newly diagnosed 2021, than half new diagnoses made China. Our initial...
The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV) infections by 2030. However, HBV prevalence in Western countries, where historical is low and highly impacted immigration trends, remains uncertain making planning difficult. We aimed to develop a more accurate estimate identify key immigrant populations that need be screened, vaccinated, treated achieve targets.US data from 1900 forward country-specific modeled age sex were used immigrated entering US, new...
Cost-effective screening strategies are needed to make hepatitis C virus (HCV) elimination a reality. We determined if birth cohort is cost-effective in Italy.
Chronic hepatitis B virus (HBV) infection is a leading cause of liver disease and related mortality globally. However, most the infected individuals in United States remain undiagnosed untreated. There need to understand more completely economic burden impact removing treatment restrictions increasing diagnosis treatment. The PRoGReSs model, dynamic HBV model that tracks population by year, stage, gender, was used quantify chronic from 2020 2050 based on four scenarios: status quo (base)...
Summary Due to the introduction of newer, more efficacious treatment options, there is a pressing need for policy makers and public health officials develop or adapt national hepatitis C virus ( HCV ) control strategies changing epidemiological landscape. To do so, detailed, country‐specific data are needed characterize burden chronic infection. In this study 17 countries, literature review published unpublished on prevalence, viraemia, genotype, age gender distribution, liver transplants...
Advances in direct-acting antiviral treatment of HCV have reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated the possible impact only diagnosed and linked-to-care individuals on overall burden estimates identified a strategy to achieve WHO targets by 2030.Using modelling approach grounded Italian real-life data treated patients, different linkage-to-care scenarios were built evaluate potential strategies achieving elimination goals.Under 40%...
Summary Factors influencing the morbidity and mortality associated with viremic hepatitis C virus (HCV) infection change over time place, making it difficult to compare reported estimates. Models were developed for 17 countries (Bahrain, Bulgaria, Cameroon, Colombia, Croatia, Dominican Republic, Ethiopia, Ghana, Hong Kong, Jordan, Kazakhstan, Malaysia, Morocco, Nigeria, Qatar Taiwan) quantify characterize population as well forecast changes in infected corresponding disease burden from 2015...
Summary The hepatitis C virus ( HCV ) epidemic was forecasted through 2030 for 17 countries in Africa, Asia, Europe, Latin America and the Middle East, interventions achieving Global Health Sector Strategy on viral targets—“ WHO Targets” (65% reduction ‐related deaths, 90% new infections of diagnosed by 2030) were considered. Scaling up treatment diagnosis rates over time would be required to achieve these targets all but one country, even with introduction high SVR therapies. scenarios...
Abstract Background The last two decades have seen substantial expansion of childhood vaccination programmes in low and middle income countries (LMICs). Here we quantify the health impact these by estimating deaths disability-adjusted life years (DALYs) averted with ten antigens 98 LMICs between 2000 2030. Methods Independent research groups provided model-based disease burden estimates under a range coverage scenarios for pathogens: hepatitis B (HepB), Haemophilus influenzae type b (Hib),...
Abstract Background & Aims Egypt used to have one of the highest prevalences HCV infection worldwide. The Egyptian Ministry Health launched a national campaign for detection and management reduce its burden. This study aims carry out cost‐effectiveness analysis evaluate costs benefits screening treatment programme. Methods A disease burden economic impact model was populated with programme data assess direct medical costs, health effects measured in disability‐adjusted life years...